ACEMETACIN

Details

Stereochemistry	ACHIRAL
Molecular Formula	C21H18ClNO6
Molecular Weight	415.824
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC1=CC2=C(C=C1)N(C(=O)C3=CC=C(Cl)C=C3)C(C)=C2CC(=O)OCC(O)=O

InChI

InChIKey=FSQKKOOTNAMONP-UHFFFAOYSA-N

InChI=1S/C21H18ClNO6/c1-12-16(10-20(26)29-11-19(24)25)17-9-15(28-2)7-8-18(17)23(12)21(27)13-3-5-14(22)6-4-13/h3-9H,10-11H2,1-2H3,(H,24,25)

HIDE SMILES / InChI

Molecular Formula	C21H18ClNO6
Molecular Weight	415.824
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.medicines.org.uk/emc/medicine/1145

Acemetacin is a non-steroidal anti-inflammatory drug used for the treatment of osteoarthritis, rheumatoid arthritis, lower back pain, and relieving post-operative pain. It is manufactured by Merck KGaA under the tradename Emflex and is available in the UK as a prescription-only drug. Other brand names for acemetacin include Rheutrop (Austria), Acemetadoc, Acephlogont, Azeat, Rantudil (Germany, Hungary, Mexico, Portugal, Turkey), Gamespir (Greece), Oldan, Reudol (Spain), Tilur (Switzerland), Ost-map (Egypt). Acemetacin is a glycolic acid ester of indomethacin. The pharmacological activity resulting from acemetacin administration in man is derived from the presence of both acemetacin and indomethacin. The precise pharmacological mode of action of acemetacin is not known. However, unlike other NSAIDs, acemetacin is only a relatively weak inhibitor of prostaglandin synthetase. Prostaglandins are known to have an antisecretory and cytoprotective effect on the gastric mucosa. Acemetacin shows activity in many of the established in vitro tests of anti-inflammatory activity including inhibition of the release of a number of mediators of inflammation. Acemetacin is well absorbed after oral administration. Its major metabolite is indomethacin, which, after repeated administration is present at levels in excess of those of acemetacin. Acemetacin is bound to plasma protein to a slightly lesser extent than indomethacin and has a relatively short plasma elimination half-life. It is eliminated by both hepatic and renal mechanisms. The pharmacokinetics appear to be linear at recommended therapeutic doses, unaffected by moderate renal or hepatic impairment, and unchanged in the elderly.

Approval Year

Conditions

Condition	Modality	Highest Phase	Product
Rheumatoid arthritis 320 Sources: https://www.medicines.org.uk/emc/medicine/1145	Palliative	Approved 8583	Emflex Capsules Approved Use Unknown Launch Date 1990
Osteoarthritis 157 Sources: https://www.medicines.org.uk/emc/medicine/1145	Palliative	Approved 8583	Emflex Capsules Approved Use Unknown Launch Date 1990
Low back pain 22 Sources: https://www.medicines.org.uk/emc/medicine/1145	Palliative	Approved 8583	Emflex Capsules Approved Use Unknown Launch Date 1990

C_max

Value	Dose	Analyte	Population
245 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1888622/	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	ACEMETACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FED
187 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1888622/	60 mg 2 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	ACEMETACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FED
705 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1888622/	60 mg 2 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	INDOMETHACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FED
632 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1888622/	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	INDOMETHACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FED
268 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1888622/	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	ACEMETACIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FED
277 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1888622/	60 mg 2 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	ACEMETACIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FED
555 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1888622/	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	INDOMETHACIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FED
804 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1888622/	60 mg 2 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	INDOMETHACIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FED

AUC

Value	Dose	Analyte	Population
589 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1888622/	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	ACEMETACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FED
483 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1888622/	60 mg 2 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	ACEMETACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FED
6349 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1888622/	60 mg 2 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	INDOMETHACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FED
4596 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1888622/	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	INDOMETHACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FED
664 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1888622/	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	ACEMETACIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FED
712 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1888622/	60 mg 2 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	ACEMETACIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FED
4296 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1888622/	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	INDOMETHACIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FED
7586 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1888622/	60 mg 2 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	INDOMETHACIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FED

T_1/2

Value	Dose	Analyte	Population
1.03 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1888622/	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	ACEMETACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FED
1.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1888622/	60 mg 2 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	ACEMETACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FED
7.07 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1888622/	60 mg 2 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	INDOMETHACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FED
6.01 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1888622/	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	INDOMETHACIN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FED
1.03 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1888622/	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	ACEMETACIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FED
2.27 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1888622/	60 mg 2 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	ACEMETACIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FED
6.12 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1888622/	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	INDOMETHACIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FED
7.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1888622/	60 mg 2 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	INDOMETHACIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FED

Doses

Dose	Population	Adverse events
60 mg 3 times / day multiple, oral Recommended Dose: 60 mg, 3 times / day Route: oral Route: multiple Dose: 60 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2004546/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/2004546/	Disc. AE: Gastric pain, Dyspepsia... AEs leading to discontinuation/dose reduction: Gastric pain Dyspepsia Diarrhea Headache Sources: https://pubmed.ncbi.nlm.nih.gov/2004546/

AEs

AE	Significance	Dose	Population
Diarrhea	Disc. AE	60 mg 3 times / day multiple, oral Recommended Dose: 60 mg, 3 times / day Route: oral Route: multiple Dose: 60 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2004546/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/2004546/
Dyspepsia	Disc. AE	60 mg 3 times / day multiple, oral Recommended Dose: 60 mg, 3 times / day Route: oral Route: multiple Dose: 60 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2004546/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/2004546/
Gastric pain	Disc. AE	60 mg 3 times / day multiple, oral Recommended Dose: 60 mg, 3 times / day Route: oral Route: multiple Dose: 60 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2004546/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/2004546/
Headache	Disc. AE	60 mg 3 times / day multiple, oral Recommended Dose: 60 mg, 3 times / day Route: oral Route: multiple Dose: 60 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2004546/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/2004546/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2252	inhibitor 2438	inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 2153 BCRP 910 P-gp 1741 CYP2C19 2057 CYP2E1 1060 OATP1B3 961 CYP2A6 879 OATP1B1 1079 CES1 7 CYP19A1 429 OATP2B1 157	P-gp 2052

Drug as perpetrator

Target	Modality	Activity
CYP1A2 2333	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzMzU2IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE4OTE3MSJ9fQ==	no [IC50 >10 uM]
CYP2A6 911	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE4OTE3MSJ9fQ==	no [IC50 >10 uM]
CYP2C19 2141	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNjIyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE4OTE3MSJ9fQ==	no [IC50 >10 uM]
CYP2C9 2497	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzMzk3IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE4OTE3MSJ9fQ==	no [IC50 >10 uM]
CYP2D6 2546	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwyODkiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMMTg5MTcxIn19	no [IC50 >10 uM]
CYP2E1 1146	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgxIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE4OTE3MSJ9fQ==	no [IC50 >10 uM]
CYP3A4 2633	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNDAiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMMTg5MTcxIn19	no [IC50 >10 uM]
BCRP 985	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/1981#section=BioAssay-Results Page: 72.0	no
CYP19A1 430	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/1981#section=BioAssay-Results Page: 426.0	no
OATP2B1 162	inhibitor 4027 Sources: https://transportal.compbio.ucsf.edu/compounds/acemetacin/	yes [IC50 0.1 uM]
OATP1B1 1095	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxNjk3NjY4IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE4OTE3MSJ9fQ==	yes [Inhibition 10 uM]
OATP1B3 970	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxNzQzMTIxIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE4OTE3MSJ9fQ==	yes [Inhibition 10 uM]
CES1 7	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/19225040/	yes
P-gp 1932	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/1981#section=BioAssay-Results Page: 17.0	yes

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 2052	substrate 4014 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/1981#section=BioAssay-Results Page: 400.0	no

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwyNDAiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMMTg5MTcxIn19

PubMed

Title	Date	PubMed
A double-blind, randomized, controlled parallel group study evaluating the efficacy and safety of acemetacin for the management of osteoarthritis.	2002	12395912
[The hydroxam reaction of indometacin and acemetacin].	2003 Jun	12857012
Treatment of congenital nephrogenic diabetes insipidus with hydrochlorothiazide and amiloride in an adult patient.	2004	14646392
Risk of breast cancer among users of aspirin and other anti-inflammatory drugs.	2004 Aug 2	15226764
Interaction of antiinflammatory drugs with EPC liposomes: calorimetric study in a broad concentration range.	2004 Feb	14747330
Simultaneous determination of several antalgic drugs based on their interactions with beta-cyclodextrin by capillary zone electrophoresis.	2004 Mar	15023252
Comparison between sodium dodecylsulphate and cetyltrimethylammonium bromide as mobile phases in the micellar liquid chromatography determination of non-steroidal anti-inflammatory drugs in pharmaceuticals.	2004 Oct 29	15496335
Prescribing of COX-2 inhibitors in Germany after safety warnings and market withdrawals.	2006 Oct	17069430
Polyproline-rod approach to isolating protein targets of bioactive small molecules: isolation of a new target of indomethacin.	2007 Jan 31	17243824
Accuracy of drug advertisements in medical journals under new law regulating the marketing of pharmaceutical products in Switzerland.	2008 Dec 31	19117521
Patients with rheumatoid arthritis have an altered circulatory aggrecan profile.	2008 May 28	18507823
Lack of effects of acemetacin on signalling pathways for leukocyte adherence may explain its gastrointestinal safety.	2008 Nov	18695646
Bartter's syndrome with type 2 diabetes mellitus.	2009 Feb	19251537
Risk of Upper Gastrointestinal Bleeding in a Cohort of New Users of Low-Dose ASA for Secondary Prevention of Cardiovascular Outcomes.	2010	21811460
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method.	2010 Dec	21818443
High-throughput microplate assay for the determination of drug partition coefficients.	2010 Nov	21030957
Development and evaluation of pharmacosomes of aceclofenac.	2010 Sep	21694988

Patents

Sample Use Guides

In Vivo Use Guide

The recommended starting dose is 120 mg/day in divided doses, increasing to 180 mg/day in divided doses, depending on patient response

Route of Administration: Oral

In Vitro Use Guide

acemetacin exhibited concentration-dependent effects against O(2)(-).

Substance Class	Chemical Created by `admin` on `Wed Apr 02 09:59:16 GMT 2025` Edited by `admin` on `Wed Apr 02 09:59:16 GMT 2025`
Record UNII	5V141XK28X
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ACEMETACIN

Official Name

English

RANTUDIL

Preferred Name

English

Acemetacin [WHO-DD]

Common Name

English

acemetacin [INN]

Common Name

English

NSC-757413

Code

English

1-(P-CHLOROBENZOYL)-5-METHOXY-2-METHYLINDOLE-3-ACETIC ACID ESTER WITH GLYCOLIC ACID

Common Name

English

ACEMETACIN [JAN]

Common Name

English

ACEMETACIN [MI]

Common Name

English

ACEMETACIN [EP MONOGRAPH]

Common Name

English

ACEMETACIN [MART.]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C257